NCT06589440

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Stingray Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.

Conditions

• Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Interventions

Type	Name	Description
DRUG	SR-8541A	SR-8541A administered orally in combination with intravenous botensilimab and balstilimab

Timeline

• Start date: 2024-11-20
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2024-09-19
• Last updated: 2026-01-15

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study